Difference between revisions of "Vinflunine (Javlor)"
Jump to navigation
Jump to search
m |
m |
||
| (One intermediate revision by the same user not shown) | |||
| Line 3: | Line 3: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | |||
*[[Breast cancer]] | *[[Breast cancer]] | ||
| + | *[[Non-small cell lung cancer]] | ||
| + | *[[Urothelial carcinoma]] | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
| Line 19: | Line 20: | ||
[[Category:Vinca alkaloids]] | [[Category:Vinca alkaloids]] | ||
| − | |||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
| + | [[Category:Non-small cell lung cancer medications]] | ||
| + | [[Category:Urothelial carcinoma medications]] | ||
[[Category:EMA approved in 2009]] | [[Category:EMA approved in 2009]] | ||
Latest revision as of 12:26, 27 July 2024
Mechanism of action
From the NCI drug dictionary: A bi-fluorinated derivative of the semi-synthetic vinca alkaloid vinorelbine with antitubulin, antineoplastic, and antiangiogenic activities. Vinflunine inhibits tubulin assembly without any stablization of assembled microtubules at concentrations comparable to those of other vinca alkaloids such as vincristine, vinblastine and vinorelbine; this effect on microtubule dynamics results in cell cycle arrest in mitosis and apoptosis. Compared to other vinca alkaloids, this agent binds weakly to the vinca-binding site, indicating that vinflunine may exhibit reduced neurotoxicity.
Diseases for which it is used
History of changes in EMA indication
- 2009-09-21: Initial marketing authorization at Javlor.
Also known as
- Brand name: Javlor